Advancing Aortic Technologies
with Purpose™

Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and to deliver breakthrough technologies of unsurpassed quality that have far-reaching impact.
Meet Artivion
Man looking at item at a store

January 27, 2025

Late-Breaking Data from AMDS PERSEVERE Trial at the 61stSociety of Thoracic Surgery Annual Meeting

Today we announced data from the AMDS PERSEVERE clinical trial (the “IDE”) was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation..

Man looking at item at a store

December 9, 2024

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Today, Artivion announced the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for the use of the AMDS Hybrid Prosthesis (“AMDS”) in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world’s first aortic arch remodeling device for use in treating acute DeBakey Type I aortic dissections.

Man looking at item at a store

April 29, 2024

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study

Man looking at item at a store

January 29, 2024

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion

Man looking at item at a store

November 9, 2023

Artivion Announces Completion of Enrollment in PERSEVERE Trial.

The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis.

Man looking at item at a store

October 5, 2023

Late-Breaking Science Presented at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

Man looking at item at a store

October 5, 2023

Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS

Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

Man looking at item at a store

July 27, 2022

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission.

Man looking at item at a store

FDA Accepts CryoLife IDE Application for PERSEVERE Pivotal IDE Study

A Prospective, Single Arm, Multi-center Clinical Investigation, to Evaluate the Saftey and Effectiveness of AMDSTM  in the Treatment of Acute DeBakey Type I Dissection

Man looking at item at a store

July 29, 2021

CryoLife Announces Sale of PerClot to Baxter

CryoLife Announces the Sale of PerClot to a subsidiary of Baxter International, Inc.

Man looking at item at a store

September 2, 2020

CryoLife Acquires Ascyrus Medical

CryoLife Acquires Ascyrus Medical LLC, Developer of AMDS Hybrid Prosthesis. Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical Dissection Stent (AMDS™), the world’s first aortic arch remodeling device used for the treatment of acute Type A aortic dissections.

When the need is aortic,
the solution is Artivion

Our intentional focus on the aorta and collaboration with the world’s foremost cardiac and vascular surgeons allow us to leverage our combined expertise in the development of new, innovative, life-changing aortic-centric technologies.

NOTE: All products and indications are not available/approved in all markets.
Please contact your local Artivion representative for details.
SURGICAL SEALANT
E-XTRA DESIGN ENGINEERING

Patient-Powered Progress

We provide solutions that have far-reaching impact on surgical outcomes and restoring the lives of patients fighting aortic diseases. Cardiac and vascular surgeons the world over—along with each patient in their care—have greatly benefited from our life-changing technologies.